Understanding the interactions between the gut microbiota and drugs is crucial for comprehending drug efficacy. The microbiota influences drug absorption, metabolism, efficacy, and toxicity. Utilizing germ-free animal models to investigate these interaction mechanisms helps optimize drug use and development, provides new insights for personalized therapy, and is key to addressing individual differences in drug efficacy.
Gnotobio Biotechnology possesses technology platforms including phenotyping, pathology, and bioinformatics, enabling the following series of services for studying drug-microbiota interaction mechanisms:
1. Pharmacokinetic/Pharmacodynamic (PK/PD) Studies in Germ-Free Mice: Using the germ-free mouse platform, drug metabolism is analyzed in conjunction with the microbiota. Metagenomic/metabolomic technologies are employed to dissect the impact of the microbiota on drug activation, inactivation, or toxicity.
2. Personalized Medication Guidance: Predicting drug responses based on patient-specific microbiota characteristics to support precision medicine.
3. Microbiota-Enhanced Drug Development: Screening for probiotics or prebiotics that synergize with drugs to enhance efficacy.
Advantages:
● Multi-Omics Integration Platform: Combined with germ-free animal models, providing mechanism-phenotype dual validation.
● High Translational Value: Outputs patentable microbiota signatures or combination therapy strategies.